Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Why NET Stock Dipped Sharply

By Chris Lau, InvestorPlace Contributor

After Nasdaq dropped, markets are selling Cloudflare and ignoring its strong growth momentum in the decade ahead.

Avoid Alibaba Stock Amid Chinese Government Regulations

By Chris Lau, InvestorPlace Contributor

Alibaba is still out of favor as the Chinese government punishes the e-commerce giant for its association with Jack Ma and his criticisms.

Twilio Stock Is a Much More Compelling Growth Play at These Prices

By Chris Lau, InvestorPlace Contributor

After topping around $400 throughout the year, TWLO stock trended lower for months and is due to end its downtrend.

7 Stocks to Buy to Benefit From the Fed’s Delayed Taper

By Chris Lau, InvestorPlace Contributor

These companies are stocks to buy because they will do well in a sustained low-interest-rate environment as the Fed holds off on buying debt.

Cloudflare Stock Still Has Exceptional Growth Ahead If You’re Patient Enough

By Chris Lau, InvestorPlace Contributor

NET stock may have fallen sharply last week to around $159 but it creates an entry price for growth investors.

Why DraftKings Stock Is Worth Watching After a Big Drop

By Chris Lau, InvestorPlace Contributor

DraftKings faces license delays in at least two states, adding uncertainty to its near-term outlook and hurting its stock price.

Why You Should Buy Moderna Stock at Every Dip

By Chris Lau, InvestorPlace Contributor

Moderna’s cash growth will continue as demand for booster shots and vaccines for the omicron variant increase, giving a boost to MRNA stock.

What to Do With Didi After Panicked Investors Sold off Shares

By Chris Lau, InvestorPlace Contributor

DIDI stock announced plans to delist, creating a permanent loss for shareholders while offering a potential opportunity for speculators.

7 China Stocks on Fire Sale Following Alibaba’s Tumble

By Chris Lau, InvestorPlace Contributor

China-based companies are valued at multi-year lows and at levels that are close to pricing the risks of harsh government regulations.

Why Buy And Hold CPNG Stock For the Long-term

By Chris Lau, InvestorPlace Contributor

Markets continue to ignore Coupang’s growth prospects in Eats and Fresh, along with the strong core business.

Load More